Real life hexavalent vaccination among children as a practical guide for public health professionals: Four years (from 2016 to 2019) of clinical practice in Sicily, Italy

References

• Esposito S, Bonanni P, Maggi S, Tan L, Ansaldi F, Lopalco PL, Dagan R, Michel J-P, van Damme P, Gaillat J, et al. Recommended immunization schedules for adults: clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid). Hum Vaccin Immunother. 2016;12(7):1–9. doi:10.1080/21645515.2016.1150396.
   PubMed Web of Science ®Google Scholar
• Agenzia Italiana del Farmaco. Vaccini Obbligatori e a Offerta Gratuita e Attiva (Legge 119/2017). [accessed 2022 July 5]. https://www.aifa.gov.it/vaccini-obbligatori-e-a-offerta-gratuita-e-attiva-legge-119-2017#: {}:text=ANTI%2DEPATITE%20B,ENGERIX%20B%20uso&text=HEXYON%20(EPATITE%20B%20%2D%20POLIO%20%2D,%2D%20EPATITE%20A)%20%2D%20uso%20intramuscolare.
   Google Scholar
• Italian Ministry of Health. National vaccination plan 2017–2019. [accessed 2022 July 5]. https://www.salute.gov.it/imgs/C_17_pubblicazioni_2571_allegato.pdf.
   Google Scholar
• Obando-Pacheco P, Rivero-Calle I, Raguindin PF, Martinón-Torres F. DTaP5-HBV-IPV-Hib pediatric hexavalent combination vaccine for use in children from 6 weeks through to 4 years of age. Expert Rev Vaccines. 2019;18(11):1115–26. doi:10.1080/14760584.2019.1690457.
   PubMed Web of Science ®Google Scholar
• Block SL, Klein NP, Sarpong K, Russell S, Fling J, Petrecz M, Flores S, Xu J, Liu G, Stek JE, et al. Lot-to-lot consistency, safety, tolerability and immunogenicity of an investigational hexavalent vaccine in US infants. Pediatr Infect Dis J. 2017;36(2):202–08. doi:10.1097/inf.0000000000001405.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Becker T, Vertruyen AF, Poschet K, Flores SA, Pagnoni MF, Xu J, Liu GF, Stek JE, Boisnard F, et al. A phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at two, three, four and twelve months. Pediatr Infect Dis J. 2017;36(2):209–15. doi:10.1097/inf.0000000000001406.
   PubMed Web of Science ®Google Scholar
• Decker MD. MPH principles of pediatric combination vaccines and practical issues related to use in clinical practice. Pediatr Infect Dis J. 2001;20(11):S10–8. doi:10.1097/00006454-200111001-00002.
   PubMed Web of Science ®Google Scholar
• Hexyon®, RCP. AIFA website. https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/farmaco?farmaco=04281.
   Google Scholar
• Vaxelis®, RCP. AIFA website.
   Google Scholar
• GlaxoSmithKline. Summary of product characteristics (Infanrix hexa™). Rixensart: GlaxoSmithKline; 2002.
   Google Scholar
• Tregnaghi MW, Zambrano B, Santos-Lima E. Immunogenicity and safety of an investigational hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-hepatitis B-Haemophilus influenzae B conjugate combined vaccine in healthy 2-, 4-, and 6-month-old Argentinean infants. Pediatr Infect Dis J. 2011;30(6):e88–96. doi:10.1097/INF.0b013e318212eb80.
   PubMed Web of Science ®Google Scholar
• Maman K, Zöllner Y, Greco D, Duru G, Sendyona S, Remy V. The value of childhood combination vaccines: from beliefs to evidence. Hum Vaccin Immunother. 2015;11(9):2132–41. doi:10.1080/21645515.2015.1044180.
   PubMed Web of Science ®Google Scholar
• Chiappini E, Petrolini C, Caffarelli C, Calvani M, Cardinale F, Duse M, Licari A, Manti S, Martelli A, Minasi D, et al. Hexavalent vaccines in preterm infants: an update by Italian Society of Pediatric Allergy and Immunology jointly with the Italian Society of Neonatology. Ital J Pediatr. 2019;45(1):145. doi:10.1186/s13052-019-0742-7.
   PubMed Web of Science ®Google Scholar
• Orsi A, Azzari C, Bozzola E, Chiamenti G, Chirico G, Esposito S, Francia F, Lopalco P, Prato R, Russo R, et al. Hexavalent vaccines: characteristics of available products and practical considerations from a panel of Italian experts. J Prev Med Hyg. 2018;59(2):E107–19.
   PubMedGoogle Scholar
• European Medicine Agency. Rotatix summary of product characteristics. [accessed 2022 Mar 21]. https://www.ema.europa.eu/documents/product-information/rotarix-epar-product-information_en.pdf.
   Google Scholar
• European Medicine Agency. Rotateq Summary of Product Characteristics. [accessed 2022 Mar 21]. https://www.ema.europa.eu/documents/product-information/rotateq-epar-product-information_en.pdf.
   Google Scholar
• European Medicine Agency. Prevenar Summary of Product Characteristics. [accessed 2022 Mar 21]. https://www.ema.europa.eu/en/medicines/human/EPAR/prevenar#product-information-section.
   Google Scholar
• European Medicine Agency. Prevenar 13 summary of product characteristics. [accessed 2022 Mar 21]. https://www.ema.europa.eu/en/medicines/human/EPAR/prevenar-13.
   Google Scholar
• European Medicine Agency. Synflorix summary of product characteristics. [accessed 2022 Mar 21]. https://www.ema.europa.eu/en/medicines/human/EPAR/synflorix.
   Google Scholar
• European Medicine Agency. Bexsero summary of product characteristics. [accessed 2022 Mar 21]. https://www.ema.europa.eu/en/medicines/human/EPAR/bexsero.
   Google Scholar
• European Medicine Agency. Menveo summary of product characteristics. [accessed 2022 Mar 21]. https://www.ema.europa.eu/en/medicines/human/EPAR/menveo.
   Google Scholar
• European Medicine Agency. Nimenrix summary of product characteristics. [accessed 2022 Mar 21]. https://www.ema.europa.eu/en/medicines/human/EPAR/nimenrix.
   Google Scholar
• European Medicine Agency. Proquad summary of product characteristics. [accessed 2022 Mar 21]. https://www.ema.europa.eu/en/medicines/human/EPAR/proquad.
   Google Scholar
• Schmitt H-J, Steul KS, Borkowski A, Ceddia F, Ypma E, Knuf M. Two versus three doses of a meningococcal C conjugate vaccine concomitantly administered with a hexavalent DTaP-IPV-HBV/Hib vaccine in healthy infants. Vaccine. 2008;26(18):2242–52. doi:10.1016/j.vaccine.2008.02.041.
   PubMed Web of Science ®Google Scholar
• [accessed 2022 Jul 6]. https://demo.istat.it/.
   Google Scholar
• AIFA - Area Vigilanza Post-marketing. Rapporto Vaccini 2018. Gov.It; 2019 Jul 30 [accessed 2022 Aug 11]. https://www.aifa.gov.it/documents/20142/241056/Rapporto+Vaccini+2018.pdf/62975a0e-a836-da32-f7b9-1e39196374dd.
   Google Scholar
• Plans-Rubió P. Evaluation of the establishment of herd immunity in the population by means of serological surveys and vaccination coverage. Hum Vaccin Immunother. 2012;8(2):184–88. doi:10.4161/hv.18444.
   PubMed Web of Science ®Google Scholar
• Klein NP, Abu-Elyazeed R, Cheuvart B, Janssens W, Mesaros N. Immunogenicity and safety following primary and booster vaccination with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccine: a randomized trial in the United States. Hum Vaccin Immunother. 2019;15(4):809–21. doi:10.1080/21645515.2018.1549449.
   PubMed Web of Science ®Google Scholar
• Martinón-Torres F, Boisnard F, Thomas S, Sadorge C, Borrow R. Immunogenicity and safety of a new hexavalent vaccine (DTaP5-IPV-HB-Hib) administered in a mixed primary series schedule with a pentavalent vaccine (DTaP5-IPV-Hib). Vaccine. 2017;35(30):3764–72. doi:10.1016/j.vaccine.2017.05.043.
   PubMed Web of Science ®Google Scholar
• Stein-Zamir C, Israeli A. Age-appropriate versus up-to-date coverage of routine childhood vaccinations among young children in Israel. Hum Vaccin Immunother. 2017;13(9):2102–10. doi:10.1080/21645515.2017.1341028.
   PubMed Web of Science ®Google Scholar
• Kwak GY, Kwon HJ, Kim JH, Kim HM, Park JS, Ma SH, Kim JG, Kang JH. The immunogenicity and safety of DTaP interchangeable immunization among Korean children. Vaccine. 2012;30(31):4644–47. doi:10.1016/j.vaccine.2012.04.094.
   PubMed Web of Science ®Google Scholar
• Knuf M, Haas H, Garcia-Corbeira P, Turriani E, Mukherjee P, Janssens W, Berlaimont V. Hexavalent vaccines: what can we learn from head-to-head studies? Vaccine. 2021;39(41):6025–36. doi:http://dx.doi.org/10.1016/j.vaccine.2021.08.086.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Karvonen A, Prymula R, Schuster V, Tejedor JC, Thollot F, Garcia-Corbeira P, Damaso S, Han H-H, Bouckenooghe A. Immunogenicity and safety of the human rotavirus vaccine Rotarix™ co-administered with routine infant vaccines following the vaccination schedules in Europe. Vaccine. 2010;28(32):5272–79. doi:http://dx.doi.org/10.1016/j.vaccine.2010.05.057.
   PubMed Web of Science ®Google Scholar
• Italian Ministry of Health. Recommended vaccination during pregnant and childbearing age women. 2022 Apr 27. https://www.trovanorme.salute.gov.it/norme/renderNormsanPdf?anno=2019&codLeg=71540&parte=1%20&serie=null.
   Google Scholar
• Costantino C, Mazzucco W, Bonaccorso N, Cimino L, Conforto A, Sciortino M, Catalano G, D’Anna MR, Maiorana A, Venezia R, et al. Educational interventions on pregnancy vaccinations during childbirth classes improves vaccine coverages among pregnant women in Palermo’s province. Vaccines (Basel). 2021;9(12):1455. doi:10.3390/vaccines912145.
   PubMed Web of Science ®Google Scholar
• Guglielmi G. Pandemic drives largest drop in childhood vaccinations in 30 years. Nature. 2022 Aug;608(7922):253. doi:10.1038/d41586-022-02051-w.
   PubMedGoogle Scholar